背景:为了评估中国目前的主要脊髓灰质炎疫苗接种时间表的免疫原性,并将其与使用Sabin或Salk株IPV的替代时间表进行比较(sIPV,wIPV)。
方法:在重庆的四个地点进行了横断面调查,中国,60-89天的健康婴儿被方便地招募,并根据他们接受的初级脊髓灰质炎疫苗接种时间表分为四组(2sIPV+bOPV,2wIPV+bOPV,3sIPV,和3wIPV)。末次给药后比较针对脊髓灰质炎病毒血清型(1、2和3型)的血清保护和中和抗体滴度。
结果:有408名婴儿完成了方案。在所有组中,观察到的针对脊髓灰质炎病毒1、2和3型的血清阳性均超过96%。与“2IPVbOPV”组相比,仅IPV组对2型脊髓灰质炎病毒的抗体滴度(GMT)更高(中位数:192,QR:96-384,P<0.05)。而“2IPV+bOPV”组诱导的抗脊髓灰质炎病毒1型(中位数:2048,QR:768-2048,P<0.05)和3型(中位数:2048,QR:512-2048,P<0.05)的抗体滴度明显高于仅IPV组。
结论:我们的研究结果证明,两剂IPV和一剂bOPV是目前中国最好的脊髓灰质炎常规免疫方案。
BACKGROUND: To assess the immunogenicity of the current primary polio vaccination schedule in China and compare it with alternative schedules using Sabin or Salk-strain IPV (sIPV, wIPV).
METHODS: A cross-sectional investigation was conducted at four sites in Chongqing, China, healthy infants aged 60-89 days were conveniently recruited and divided into four groups according to their received primary polio vaccination schedules (2sIPV + bOPV, 2wIPV + bOPV, 3sIPV, and 3wIPV). The sero-protection and neutralizing antibody titers against poliovirus serotypes (type 1, 2, and 3) were compared after the last dose.
RESULTS: There were 408 infants completed the protocol. The observed seropositivity was more than 96% against poliovirus types 1, 2, and 3 in all groups. IPV-only groups induced higher antibody titers(GMT) against poliovirus type 2 (Median:192, QR: 96-384, P<0.05) than the \"2IPV + bOPV\" group. While the \"2IPV + bOPV\" group induced significantly higher antibody titers against poliovirus type 1 (Median:2048, QR: 768-2048, P<0.05)and type 3 (Median:2048, QR: 512-2048, P<0.05) than the IPV-only group.
CONCLUSIONS: Our findings have proved that the two doses of IPV with one dose of bOPV is currently the best polio routine immunization schedule in China.